R. Leconte des Floris

  • Citations Per Year
Learn More
BACKGROUND AND OBJECTIVES Allogeneic bone marrow transplantation (BMT) is a widely accepted therapeutic approach in homozygous beta-thalassemia. However, the majority of patients do not have a genotypically identical donor within the family. This prompted us to conduct a pilot study to investigate the feasibility of matched unrelated bone marrow(More)
Thirty-two patients with acute leukemia, chronic granulocytic leukemia, or multiple myeloma received a T lymphocyte-depleted HLA-identical marrow. After being treated with pan-T monoclonal antibodies (MoAbs) and one round of baby rabbit complement, the mean percentage of T cell depletion was 94% ± 4%. The number of residual viable T cell infused to the(More)
Treatment of patients aff ected by Philadelphia chromosomepositive acute lymphoblastic leukemia (Ph ALL) continues to be problematic in spite of the better complete response rates (75 – 95%) achieved with induction regimens based on tyrosine kinase inhibitors (TKIs), used either alone or in combination with conventional cytotoxic chemotherapy agents [1]. Th(More)
The contamination of autologous marrow with clonogenic tumor cells has been the main argument against ABMT in acute leukemia. In a preclinical study we evaluated an active cyclophosphamide derivative named “ASTA Z 7557”. We observed that the toxic effect of this drug on CFU-GM growth was dependent on nucleated cell concentration as well as on red blood cell(More)
  • 1